Invitrogen Enters into Agreement with genOway in RNAi Field
News Dec 16, 2005
Invitrogen Corporation and genOway have announced the signing of a co-marketing agreement around RNAi related services.
Under the terms of the agreement, Invitrogen and genOway will combine Invitrogen's expertise in RNAi research technologies with genOway's portfolio of transgenesis technologies and RNAi in vivo experience to create a services platform offering RNAi vector design through the creation of RNAi transgenic rodent models.
"Combining the services of these two leading RNAi companies will provide researchers with a complete solution to ensure successful RNAi research for drug discovery and therapeutic applications," said Jon Hindar, Senior Vice President of Life Sciences at Invitrogen.
"This broad service offering has the potential to significantly accelerate target validation studies in disease research."
"RNAi continues to gain acceptance in drug discovery and development applications," explained Kader Thiam, Head of Transgenic technologies of genOway.
"Our leading in vivo RNAi technologies are strengthened by the solid in vitro applications Invitrogen has developed."
Invitrogen has built an RNAi technology portfolio in recent years, first offering a family of products under the BLOCK-iT™ name in September 2003, including short interfering RNA, kits for creating short hairpin RNA, and technologies to deliver RNAi reagents to cells and tissues.
In November 2003, Invitrogen announced that it had acquired privately-held Sequitur, Inc. of Natick, Mass. Sequitur brought to Invitrogen Stealth™ technology, a proprietary synthetic RNA molecule that holds advantages over traditional siRNA in specificity, efficacy, stability and reducing "off target" effects of silencing.
This year Invitrogen launched the BLOCK-iT™ pol II miR RNAi expression vector kits and services which combine the advantages of traditional RNAi vectors with capabilities for tissue specific expression and multiple target knockdown from the same transcript.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.